JP7251017B2 - 免疫調節ポリヌクレオチド及びその使用 - Google Patents

免疫調節ポリヌクレオチド及びその使用 Download PDF

Info

Publication number
JP7251017B2
JP7251017B2 JP2019556339A JP2019556339A JP7251017B2 JP 7251017 B2 JP7251017 B2 JP 7251017B2 JP 2019556339 A JP2019556339 A JP 2019556339A JP 2019556339 A JP2019556339 A JP 2019556339A JP 7251017 B2 JP7251017 B2 JP 7251017B2
Authority
JP
Japan
Prior art keywords
cancer
tumor
cells
antibody
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019556339A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020516305A (ja
JP2020516305A5 (enExample
Inventor
タオ ファン，
ヤン シャオ，
ジュン チャン，
Original Assignee
チャンチュン ファープ バイオテクノロジー カンパニー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by チャンチュン ファープ バイオテクノロジー カンパニー リミテッド filed Critical チャンチュン ファープ バイオテクノロジー カンパニー リミテッド
Publication of JP2020516305A publication Critical patent/JP2020516305A/ja
Publication of JP2020516305A5 publication Critical patent/JP2020516305A5/ja
Application granted granted Critical
Publication of JP7251017B2 publication Critical patent/JP7251017B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2019556339A 2017-04-18 2018-04-17 免疫調節ポリヌクレオチド及びその使用 Active JP7251017B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201710251198.4A CN108728444A (zh) 2017-04-18 2017-04-18 免疫调节性多核苷酸及其应用
CN201710251198.4 2017-04-18
PCT/CN2018/083435 WO2018192505A1 (en) 2017-04-18 2018-04-17 Immunomodulatory polynucleotides and uses thereof

Publications (3)

Publication Number Publication Date
JP2020516305A JP2020516305A (ja) 2020-06-11
JP2020516305A5 JP2020516305A5 (enExample) 2021-05-27
JP7251017B2 true JP7251017B2 (ja) 2023-04-04

Family

ID=63855596

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019556339A Active JP7251017B2 (ja) 2017-04-18 2018-04-17 免疫調節ポリヌクレオチド及びその使用

Country Status (5)

Country Link
US (1) US11326170B2 (enExample)
EP (1) EP3612633A4 (enExample)
JP (1) JP7251017B2 (enExample)
CN (2) CN108728444A (enExample)
WO (1) WO2018192505A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210122778A1 (en) * 2019-10-21 2021-04-29 Northwestern University Spherical nucleic acids with dendritic ligands
CN113058033B (zh) * 2019-12-16 2024-07-09 远大赛威信生命科学(南京)有限公司 一种用于预防和治疗乙型肝炎的药物组合物及其用途
CN113521275B (zh) * 2020-04-17 2024-06-25 北京科兴中维生物技术有限公司 一种复合佐剂及使用该复合佐剂的新冠covid-19重组蛋白疫苗
CN113521273A (zh) * 2020-04-17 2021-10-22 北京科兴中维生物技术有限公司 一种使用含有CpG寡聚脱氧核苷酸的复合佐剂的新冠COVID-19灭活疫苗
CN113521274B (zh) * 2020-04-17 2024-06-25 北京科兴中维生物技术有限公司 一种covid-19灭活疫苗组合物及应用
CN113521267B (zh) * 2020-04-17 2024-06-25 北京科兴中维生物技术有限公司 一种covid-19重组蛋白疫苗组合物及应用
WO2021249116A1 (en) 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Coronavirus vaccine compositions, methods, and uses thereof
IL303350A (en) 2020-12-04 2023-08-01 Macrogenics Inc Pharmaceutical compositions of a her2/neu antibody and use of the same
CN115252772A (zh) * 2021-04-30 2022-11-01 华普生物技术(江苏)股份有限公司 人工合成的含CpG单链脱氧寡核苷酸在疫苗中的应用
CN114807153A (zh) * 2022-05-13 2022-07-29 南京吉盛澳玛生物医药有限公司 多种具有免疫刺激活性的CpG寡聚脱氧核苷酸及其应用
CA3257283A1 (en) * 2022-06-01 2023-12-07 Syncromune, Inc. CANCER TREATMENT METHOD BY LYSIS OF TUMOR CELLS AND INTRATUMORAL ADMINISTRATION OF COMBINATIONS OF IMMUNOTHERAPEUTIC INGREDIENTS
CN115368463B (zh) * 2022-07-19 2025-12-19 合肥天港免疫药物有限公司 双特异性抗体及其应用
CN117568339A (zh) * 2023-01-19 2024-02-20 华普生物技术(河北)股份有限公司 CpG寡核苷酸及其应用
CN118356486A (zh) * 2023-01-19 2024-07-19 华普生物技术(河北)股份有限公司 CpG佐剂在制备新型冠状病毒疫苗中的应用
CN120053634A (zh) * 2023-11-30 2025-05-30 华普石家庄医药有限公司 一种水痘带状疱疹疫苗组合物及其用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006508693A (ja) 2002-08-19 2006-03-16 コーリー ファーマシューティカル グループ，インコーポレイテッド 免疫刺激性核酸
JP2008516634A (ja) 2004-10-20 2008-05-22 コーリー ファーマシューティカル グループ，インコーポレイテッド セミソフトｃクラス免疫刺激性オリゴヌクレオチド
JP2009028031A (ja) 2007-05-18 2009-02-12 Coley Pharmaceutical Gmbh 強化された免疫刺激活性を有するリン酸が修飾されたオリゴヌクレオチド類似体
WO2015181298A1 (en) 2014-05-28 2015-12-03 Technische Universität Dresden Pharmaceutical combinations for immunotherapy
WO2017057540A1 (ja) 2015-09-30 2017-04-06 塩野義製薬株式会社 免疫賦活活性を有する核酸誘導体

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
ATE102631T1 (de) 1988-11-11 1994-03-15 Medical Res Council Klonierung von immunglobulin sequenzen aus den variabelen domaenen.
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
DE69334255D1 (de) 1992-02-06 2009-02-12 Novartis Vaccines & Diagnostic Marker für Krebs und biosynthetisches Bindeprotein dafür
US5658738A (en) 1994-05-31 1997-08-19 Becton Dickinson And Company Bi-directional oligonucleotides that bind thrombin
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
WO2004056875A1 (en) 2002-12-23 2004-07-08 Wyeth Antibodies against pd-1 and uses therefor
EP2418278A3 (en) 2005-05-09 2012-07-04 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
KR101607288B1 (ko) 2005-07-01 2016-04-05 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
JPWO2007119815A1 (ja) * 2006-04-14 2009-08-27 協和発酵キリン株式会社 Ｔｏｌｌ様受容体９作動薬
WO2008073959A2 (en) * 2006-12-12 2008-06-19 Idera Pharmaceuticals, Inc. Synthetic agonists of tlr9
EP2535354B1 (en) 2007-06-18 2017-01-11 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
CA3128656A1 (en) 2007-08-22 2009-02-26 The Regents Of The University Of California Activatable binding polypeptides and methods of identification and use thereof
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
HUE030807T2 (en) 2008-09-26 2017-05-29 Dana Farber Cancer Inst Inc Human anti-PD-1, anti-PD-L1 and anti-PD-L2 antibodies and their applications
US8895702B2 (en) 2008-12-08 2014-11-25 City Of Hope Development of masked therapeutic antibodies to limit off-target effects; application to anti-EGFR antibodies
CN102482347B (zh) 2009-01-12 2017-04-26 希托马克斯医疗有限责任公司 修饰抗体组合物及其制备和使用方法
CN104961829B (zh) 2009-11-24 2018-08-21 米迪缪尼有限公司 针对b7-h1的靶向结合剂
DK2699264T3 (en) 2011-04-20 2018-06-25 Medimmune Llc ANTIBODIES AND OTHER MOLECULES BINDING B7-H1 AND PD-1
AU2012288413B2 (en) 2011-07-24 2016-10-13 Curetech Ltd. Variants of humanized immunomodulatory monoclonal antibodies
KR101981873B1 (ko) 2011-11-28 2019-05-23 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
CN102719436A (zh) 2012-06-27 2012-10-10 南开大学 一种寡核苷酸及其制备在防治心肌肥大与心力衰竭药物中的用途
AR095882A1 (es) 2013-04-22 2015-11-18 Hoffmann La Roche Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006508693A (ja) 2002-08-19 2006-03-16 コーリー ファーマシューティカル グループ，インコーポレイテッド 免疫刺激性核酸
JP2008516634A (ja) 2004-10-20 2008-05-22 コーリー ファーマシューティカル グループ，インコーポレイテッド セミソフトｃクラス免疫刺激性オリゴヌクレオチド
JP2009028031A (ja) 2007-05-18 2009-02-12 Coley Pharmaceutical Gmbh 強化された免疫刺激活性を有するリン酸が修飾されたオリゴヌクレオチド類似体
WO2015181298A1 (en) 2014-05-28 2015-12-03 Technische Universität Dresden Pharmaceutical combinations for immunotherapy
WO2017057540A1 (ja) 2015-09-30 2017-04-06 塩野義製薬株式会社 免疫賦活活性を有する核酸誘導体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
International Immunopharmacology，2013年，vol.15，p.89-96

Also Published As

Publication number Publication date
CN108728444A (zh) 2018-11-02
CN110753756A (zh) 2020-02-04
EP3612633A1 (en) 2020-02-26
JP2020516305A (ja) 2020-06-11
WO2018192505A1 (en) 2018-10-25
US20200002704A1 (en) 2020-01-02
CN110753756B (zh) 2023-09-01
US11326170B2 (en) 2022-05-10
EP3612633A4 (en) 2021-04-28

Similar Documents

Publication Publication Date Title
JP7251017B2 (ja) 免疫調節ポリヌクレオチド及びその使用
AU2020223671B2 (en) Combination tumor immunotherapy
JP6991857B2 (ja) Ｔｌｒ９アゴニストをチェックポイント阻害剤と共に用いるがんの治療
US20250255898A1 (en) Compositions and methods for tumor immunotherapy
TW202146056A (zh) 轉穀胺醯胺酶介導之結合
JP2009500412A (ja) 癌の処置のための、抗ｃｔｌａ−４抗体とｃｐｇモチーフ含有合成オリゴデオキシヌクレオチドとの組み合わせ治療
JP2018516252A (ja) がんの処置のための抗ＩＬ−１０抗体とＣｐＧ−Ｃ型オリゴヌクレオチドの併用
EP4291243A1 (en) Lung cancer combination therapy with il-2 conjugates and an anti-pd-1 antibody or antigen-binding fragment thereof
CN114787181A (zh) 用抗pd-1/il-15免疫细胞因子靶向pd-1的新型免疫疗法
US12460208B2 (en) Immunomodulatory polynucleotides and uses thereof
CA2972757C (en) Combination tumor immunotherapy
HK1246319B (en) Combination tumor immunotherapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210414

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210414

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220531

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220719

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221121

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20221121

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20221206

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20221228

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230104

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230221

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230224

R150 Certificate of patent or registration of utility model

Ref document number: 7251017

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150